Introduction to IVUS in Peripheral Interventions

IVUS-guided revascularization is rapidly emerging as a superior alternative to traditional angiography for managing femoropopliteal occlusive disease. While angiography remains the standard, it often fails to capture precise vessel dimensions or plaque morphology. A recent Spanish study now confirms that integrating intravascular ultrasound (IVUS) significantly enhances clinical success. Furthermore, this approach reduces long-term healthcare expenditures by minimizing complications. Consequently, clinicians are increasingly viewing IVUS as an essential tool for optimizing patient outcomes in peripheral arterial disease (PAD).

Clinical Benefits of IVUS-guided revascularization

Research indicates that IVUS provides critical real-time data that angiography simply cannot match. Specifically, IVUS allows for more accurate vessel sizing and helps identify post-procedural dissections or residual stenosis. According to recent clinical trials, patients undergoing IVUS-guided procedures experience higher primary patency rates. In addition, the risk of target lesion revascularization (TLR) decreases significantly. This technical advantage is particularly evident in complex TASC C and D lesions, where vessel preparation is often more challenging. Therefore, the clinical superiority of IVUS directly translates into fewer repeat procedures and improved limb salvage.

Economic Efficiency and Dominance

The economic evaluation of IVUS-guided revascularization reveals a rare "dominant" status in healthcare. This means the technology provides better health outcomes at a lower total cost. In the Spanish base-case model, IVUS yielded an additional 0.29 quality-adjusted life-years (QALYs) per patient. Simultaneously, it saved approximately €3,289 in lifetime costs compared to angiography alone. These savings primarily stem from reduced reintervention rates and a lower incidence of major amputations. Moreover, probabilistic sensitivity analysis confirms that IVUS remains cost-effective in over 90% of simulated scenarios, even when assuming equal amputation risks.

FAQs on IVUS for Femoropopliteal Disease

How does IVUS improve primary patency?

IVUS enables precise measurement of the reference vessel diameter and lesion length. This allows for optimal balloon sizing and stent selection. Consequently, it minimizes the risk of under-expansion or residual stenosis, which are major drivers of restenosis.

Is the cost-effectiveness of IVUS applicable to India?

Yes. Given the high burden of complex PAD and diabetic foot complications in India, reducing reintervention rates is crucial. While the upfront cost of the IVUS catheter is higher, the long-term reduction in repeat hospitalizations and amputations makes it highly viable for Indian healthcare settings.

What are the key drivers of cost savings in this model?

The primary drivers are the reduced need for target lesion revascularization (TLR) and the associated costs of treating procedural complications. By optimizing the initial intervention, IVUS prevents the expensive cycle of recurrent occlusive disease.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Bretos-Azcona PE et al. Cost-effectiveness of intravascular ultrasound (IVUS) vs. angiography-guided revascularization in femoropopliteal occlusive disease. Cost Eff Resour Alloc. 2026 May 25. doi: 10.1186/s12962-026-00751-y. PMID: 42185917.

Ko YG et al. Intravascular ultrasound-guided drug-coated balloon angioplasty for femoropopliteal artery disease: a randomized clinical trial. ACC.24 Late-Breaking Clinical Trials. 2024.

Secemsky EA et al. Intravascular Ultrasound Use in Peripheral Arterial and Deep Venous Interventions: Multidisciplinary Expert Opinion From SCAI/AVF/AVLS/SIR/SVM/SVS. J Soc Cardiovasc Angiogr Interv. 2023.